Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda
NCT06232954 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5600
Last updated 2024-06-21
Summary
A cluster-randomized double-blinded control trial will be conducted in Uganda to demonstrate and quantify the protective efficacy (PE) of Mossie-GO, an active spatial repellent system disseminating transfluthrin, in reducing the prevalence of malaria in children ≤ 5 years of age, as determined by RDT positivity and confirmed by microscopy. The study's secondary objective is to measure the diversionary impact of the intervention on locally unprotected individuals and impact of the intervention on entomological correlates of transmission including vector densities, host seeking behaviour and insecticide resistance. This will be conducted using Centre of Disease Control (CDC) light traps in households, human landing catches and World Health Organisation (WHO) tube tests. Further data collection include household behavioural surveys, air sampling to quantify concentration of transfluthrin present in air, acceptability surveys and intervention safety monitoring.
Recruited households will be monitored across baseline data collection and followed up for 2 disease transmission seasons, for up to 18 months. The devices will be distributed to all consented eligible households in the two study arms: intervention and control. Intervention arm devices will be provided with transfluthrin treated discs and refill transfluthrin discs at frequent enough intervals to provide sustained protection. Households in the control arm will receive blank discs with no active ingredient. Households will be asked to continue using other malaria prevention practices, such as the use of bed nets, as recommended by national policy.
Conditions
- Malaria
- Mosquito-Borne Disease
Interventions
- DEVICE
-
Mossie-Go containing treated transfluthrin disc
The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
- DEVICE
-
Mossie-Go containing untreated blank disc
The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
Sponsors & Collaborators
-
Malaria Consortium
collaborator OTHER -
ARCTECH INNOVATION LIMITED
collaborator UNKNOWN -
Africa Power Limited
lead INDUSTRY
Principal Investigators
-
Robert Jones, PhD · Arctech Innovation
-
Jane Achan, PhD · Malaria Consortium
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Max Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-06-05
- Primary Completion
- 2025-09-30
- Completion
- 2025-09-30
Countries
- Uganda
Study Locations
More Related Trials
-
Longitudinal Antimalarial Combinations in Uganda
NCT00123552 ·Status: COMPLETED ·Phase: PHASE3
-
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
NCT05117567 ·Status: UNKNOWN ·Phase: NA
-
The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children
NCT06424002 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
NCT04327440 ·Status: COMPLETED
-
Phase 2 Efficacy Study of Primaquine and Methylene Blue
NCT02831023 ·Status: COMPLETED ·Phase: PHASE2
-
Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission
NCT01575613 ·Status: COMPLETED ·Phase: NA
-
ACT for the Home Management in Malagasy Children
NCT00612547 ·Status: COMPLETED
-
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
NCT06860178 ·Status: RECRUITING ·Phase: PHASE4
-
IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding
NCT06870344 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children
NCT01082705 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
NCT00164710 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
NCT06392152 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Seasonal R21 Mass Vaccination for Malaria Elimination
NCT06578572 ·Status: RECRUITING ·Phase: PHASE3
-
Targeted Chemo-elimination (TCE) of Malaria
NCT01872702 ·Status: COMPLETED ·Phase: NA
-
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
NCT04695197 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia
NCT04241705 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru
NCT00164216 ·Status: COMPLETED
-
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children
NCT02168569 ·Status: COMPLETED ·Phase: PHASE4
-
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
NCT05764746 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
NCT03241901 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
NCT01955382 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
NCT00140361 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence
NCT02392832 ·Status: COMPLETED ·Phase: NA
-
Severe Malaria in Remote Areas- Closing the Evidence Gap
NCT06806956 ·Status: ENROLLING_BY_INVITATION
-
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children
NCT02211729 ·Status: COMPLETED ·Phase: PHASE3